



FOR IMMEDIATE RELEASE

March 12, 2008 -- Verrow Pharmaceuticals, Inc., Holds Pre-IND Meeting with FDA on Verplatin

LENEXA, KS -- Verrow Pharmaceuticals, Inc., has successfully completed a pre-IND meeting with the Food and Drug Administration on its platinum chemotherapy, Verplatin. This will allow Verrow to file an IND (Investigational New Drug) proposal and begin Phase I clinical trials at the conclusion of ongoing pre-clinical trials in animal models.

Verplatin, based on the chemotherapy agent cisplatin, uses a proprietary platform technology to reduce the dose-limiting kidney toxicity of cisplatin. Cisplatin leads its \$1.4 billion platinum-based market segment on an infusion basis (over carboplatin and oxaliplatin). While cisplatin is considered the most effective of the platins in many disease indications, renal toxicity has been noted in 28% to 36% of patients receiving just a single dose. Over a chemotherapy cycle of multiple infusions, this nephrotoxicity causes patients to receive diminishing doses or even stop therapy altogether. Its amelioration promises to keep cisplatin patients healthier, and could improve response rates by allowing patients to finish chemo cycles at the starting dose.

ABOUT VERROW

Verrow Pharmaceuticals, Inc., a drug development company founded in 2006, is building a portfolio of lead products based on proven drugs by making them less toxic utilizing a proprietary platform technology. The modification of existing drugs allows regulatory approval through the abbreviated 505(b)(2) pathway, a cost- and time-saving strategy that has been validated by the FDA's response to Verrow's first two pre-IND submissions.

Verplatin is the second of Verrow's lead products to have a successful pre-IND meeting. The first is Vertrexate, a novel treatment for multiple sclerosis (MS), which also utilizes Verrow's proprietary platform for making nephrotoxic intravenous drugs safer. Preclinical studies are nearly complete for Vertrexate, which crosses the blood brain barrier and attacks the locus of the disease in the central nervous system. A prior version of this treatment has already demonstrated significant efficacy against MS in the clinic in over 135 patients who had failed approved therapies. Vertrexate is poised to change the paradigm for treatment of this debilitating disease.

Preparations are being made for meeting with the FDA about a third lead product, a reduced-toxicity iodinated radiocontrast agent for interventional cardiology, radiology, and computed tomography (CT).

8550 Marshall Drive, Suite 100 Lenexa, KS 66214-9836 (816) 365-3260 (913) 894-1502